dipyridamole has been researched along with Bleeding in 84 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 9.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "An extensive hemorrhage in the pharynx appeared in association with dipyridamole administration to a diabetic patient." | 7.66 | Extensive pharyngeal hemorrhage induced by dipyridamole. ( Cohen, AM; Creter, D; Djaldetti, M; Klein, B; Levinsky, UH, 1981) |
| "Dipyridamole is a platelet inhibitor that promotes anti-inflammatory effects." | 5.38 | Treatment with dipyridamole improves cardiac function and prevent injury in a rat model of hemorrhage. ( Arafah, MM; Soliman, MM, 2012) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 5.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| " The recently published European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), an open-label randomised controlled study, compared long-term treatment of patients randomised to aspirin 30-325 mg daily with (n = 1363) or without (n = 1376) dipyridamole 200 mg twice daily." | 5.12 | ESPRIT study design and outcomes--a critical appraisal. ( Einhäupl, K, 2007) |
| " With respect to intracranial hemorrhage, aspirin + clopidogrel yielded worse outcomes than 7 treatments, including placebo, apixaban, aspirin, aspirin + dipyridamole, cilostazol, clopidogrel, and dabigatran (OR, 2." | 4.95 | The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis. ( Chang, S; Chang, Y; Lu, S; Sun, Q; Zhang, Y, 2017) |
| " Cilostazol was associated with a significantly lower bleeding risk than low-dose aspirin (75-162 mg daily) and aspirin (50 mg daily) plus dipyridamole (400 mg daily)." | 4.93 | Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. ( Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y, 2016) |
| " The combination of acetylsalicylic acid (ASA) plus dipyridamole (DP) was more protective against recurrent stroke than ASA alone (RR = 0." | 4.89 | Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis. ( Donovan, JL; Kanaan, AO; Malloy, RJ; Silva, MA, 2013) |
| "A 23-year-old woman developed ischemic stroke (IS) 8 to 12 hours after ingestion of sumatriptan (ST) and then developed mucosal bleeding secondary to acute thrombocytopenia likely due to dipyridamole (DP) on the 10th day poststroke." | 4.87 | Ischemic stroke followed by acute thrombocytopenia: a double iatrogenic whammy. ( Adams, C; Ames, PR; Dhirendra, A, 2011) |
| "High-dose ASA in Heart Mate II patients treated concomitantly with warfarin is associated with an increased hazard of bleeding but does not reduce thrombotic events." | 3.83 | Antiplatelet Therapy and Adverse Hematologic Events During Heart Mate II Support. ( D'Alessandro, D; Goldstein, DJ; Guerrero, C; Jermyn, R; Jorde, UP; Kargoli, F; Levin, AP; Madan, S; Nguyen, J; Patel, SR; Saeed, O; Shah, A; Shin, J; Sims, DB, 2016) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "An extensive hemorrhage in the pharynx appeared in association with dipyridamole administration to a diabetic patient." | 3.66 | Extensive pharyngeal hemorrhage induced by dipyridamole. ( Cohen, AM; Creter, D; Djaldetti, M; Klein, B; Levinsky, UH, 1981) |
| " In the 33rd week of pregnancy, previous warfarin sodium therapy was discontinued and dipyridamole therapy instituted." | 3.65 | Cesarean section in a patient with a mitral valve prosthesis. ( Ben-Adereth, N; Biale, Y; Gueron, M; Lewenthal, H, 1975) |
| "Bleeding was defined using the International Society on Thrombosis and Haemostasis five-level ordered categorical scale: fatal, major, moderate, minor, none." | 3.30 | Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia. ( Appleton, JP; Bath, PM; Christensen, H; Dineen, RA; England, TJ; James, M; Krishnan, K; Montgomery, AA; Ranta, A; Robinson, TG; Sprigg, N; Woodhouse, LJ, 2023) |
| "Graft thrombosis is a well-recognised complication of solid organ transplantation and is one of the leading causes of graft failure." | 2.72 | Interventions for preventing thrombosis in solid organ transplant recipients. ( Hanley, J; Hoather, TJ; Surianarayanan, V; Thompson, ER; Tingle, SJ; Wilson, CH, 2021) |
| "Dipyridamole was associated with a slight increase in headache, which resolved in most patients if therapy was continued." | 2.69 | Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. ( Forbes, CD, 1998) |
| "Patients with prior stroke or transient ischemic attack (TIA) were randomized to treatment with ASA alone (50 mg daily), modified-release dipyridamole alone (400 mg daily), the two agents in a combined formulation, or placebo." | 2.68 | European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. ( Cunha, L; Diener, HC; Forbes, C; Lowenthal, A; Sivenius, J; Smets, P, 1996) |
| "Performance in patients with cerebral ischemia was poor." | 2.53 | Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study. ( Algra, A; Greving, JP; Hilkens, NA, 2016) |
| "The risk of major bleeding is increased with antiplatelet therapy." | 2.49 | Antiplatelet and anticoagulation for patients with prosthetic heart valves. ( Little, SH; Massel, DR, 2013) |
| "Bleeding is potentially the most significant antiplatelet-associated side effect." | 2.47 | Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. ( Guthrie, R, 2011) |
| "Aspirin plus ER-DP has a greater bleeding rate than clopidogrel but a lower rate than aspirin (< or =325 mg/day) alone." | 2.45 | Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? ( Brahin, E; Dessain, S; Ezekowitz, MD; Gracely, E; Nagarakanti, R; Notaro, LA; Usman, MH, 2009) |
| " For antiplatelet agents, the most important risk is excess bleeding, especially as emerging evidence suggests that excess bleeding is associated with adverse long-term outcomes; thus prevention and management of excess bleeding is critically important." | 2.45 | Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease. ( Spinler, SA, 2009) |
| "Aspirin has stood the test of time over decades as the gold standard for relatively effective, safe, and inexpensive antiplatelet therapy." | 2.40 | Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. ( Schafer, AI, 1997) |
| "Placental infarction due to thrombosis seems to be the most consistent pathological event as far as the fetus is concerned." | 2.39 | Essential thrombocythemia and pregnancy. ( Griesshammer, M; Heimpel, H; Pearson, TC, 1996) |
| "Dipyridamole is a platelet inhibitor that promotes anti-inflammatory effects." | 1.38 | Treatment with dipyridamole improves cardiac function and prevent injury in a rat model of hemorrhage. ( Arafah, MM; Soliman, MM, 2012) |
| "Hemorrhage was present in 9 cases of group B (21." | 1.30 | [Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses]. ( Azaceta, G; Civeira, E; Cornudella, R; Iturbe, T; Moreno, JA; Olave, T; Peleato, J; Sánchez, C; Varo, MJ, 1997) |
| "Aspirin was used by 91 physicians (36." | 1.28 | Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. ( Kutner, M; Nixon, G; Silverstone, F, 1991) |
| " Possible explanations for these negative findings include inadequate dosage or form of omega-3 fatty acids and the antiplatelet drugs administered, excessive variability in graft response due to uncharacterized immunologic histocompatibility, and the possible influence of non-platelet-mediated mechanisms." | 1.27 | Effects of aspirin, dipyridamole, and cod liver oil on accelerated myointimal proliferation in canine veno-arterial allografts. ( DeCampli, WM; Handen, CE; Kosek, JC; Miller, DC; Mitchell, RS, 1988) |
| "The incidence of late cardiac tamponade rose significantly (p less than 0." | 1.27 | Late postoperative tamponade following coronary artery bypass grafting in patients on antiplatelet therapy. ( Breyer, RH; Engelman, RM; Lemeshow, S; Rousou, JA, 1985) |
| "Warfarin-treated patients were at increased risk of hemorrhage (5 of 20 [25%], or 22 per 100 patient-years, vs 0 of 10 [0%], or 0 per 100 patient-years, p less than 0." | 1.27 | Anticoagulation therapy in children with mechanical prosthetic cardiac valves. ( Bradley, LM; Getson, PR; Midgley, FM; Scott, LP; Watson, DC, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (44.05) | 18.7374 |
| 1990's | 14 (16.67) | 18.2507 |
| 2000's | 17 (20.24) | 29.6817 |
| 2010's | 13 (15.48) | 24.3611 |
| 2020's | 3 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Scalia, L | 1 |
| Calderone, D | 1 |
| Capodanno, D | 1 |
| Woodhouse, LJ | 2 |
| Appleton, JP | 2 |
| Christensen, H | 2 |
| Dineen, RA | 2 |
| England, TJ | 2 |
| James, M | 2 |
| Krishnan, K | 2 |
| Montgomery, AA | 2 |
| Ranta, A | 2 |
| Robinson, TG | 2 |
| Sprigg, N | 2 |
| Bath, PM | 2 |
| Surianarayanan, V | 1 |
| Hoather, TJ | 1 |
| Tingle, SJ | 1 |
| Thompson, ER | 1 |
| Hanley, J | 1 |
| Wilson, CH | 1 |
| Sun, Q | 1 |
| Chang, S | 1 |
| Lu, S | 1 |
| Zhang, Y | 1 |
| Chang, Y | 1 |
| Beridze, M | 1 |
| Duley, L | 1 |
| Flaherty, K | 1 |
| Havard, D | 1 |
| Heptinstall, S | 1 |
| Markus, HS | 2 |
| Pocock, SJ | 1 |
| Randall, M | 1 |
| Scutt, P | 1 |
| Venables, GS | 1 |
| Levi, C | 1 |
| King, A | 1 |
| Madigan, J | 1 |
| Norris, J | 1 |
| Massel, DR | 1 |
| Little, SH | 1 |
| Malloy, RJ | 1 |
| Kanaan, AO | 1 |
| Silva, MA | 1 |
| Donovan, JL | 1 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Hilkens, NA | 1 |
| Algra, A | 1 |
| Greving, JP | 1 |
| Saeed, O | 1 |
| Shah, A | 1 |
| Kargoli, F | 1 |
| Madan, S | 1 |
| Levin, AP | 1 |
| Patel, SR | 1 |
| Jermyn, R | 1 |
| Guerrero, C | 1 |
| Nguyen, J | 1 |
| Sims, DB | 1 |
| Shin, J | 1 |
| D'Alessandro, D | 1 |
| Goldstein, DJ | 1 |
| Jorde, UP | 1 |
| Niu, PP | 1 |
| Guo, ZN | 1 |
| Jin, H | 1 |
| Xing, YQ | 1 |
| Yang, Y | 1 |
| Kent, DM | 1 |
| Thaler, DE | 1 |
| Sacco, RL | 1 |
| Diener, HC | 3 |
| Yusuf, S | 1 |
| Cotton, D | 1 |
| Ounpuu, S | 1 |
| Lawton, WA | 1 |
| Palesch, Y | 1 |
| Martin, RH | 1 |
| Albers, GW | 2 |
| Bath, P | 1 |
| Bornstein, N | 1 |
| Chan, BP | 1 |
| Chen, ST | 1 |
| Cunha, L | 2 |
| Dahlöf, B | 1 |
| De Keyser, J | 1 |
| Donnan, GA | 1 |
| Estol, C | 1 |
| Gorelick, P | 1 |
| Gu, V | 1 |
| Hermansson, K | 1 |
| Hilbrich, L | 1 |
| Kaste, M | 1 |
| Lu, C | 1 |
| Machnig, T | 1 |
| Pais, P | 1 |
| Roberts, R | 1 |
| Skvortsova, V | 1 |
| Teal, P | 1 |
| Toni, D | 1 |
| Vandermaelen, C | 1 |
| Voigt, T | 1 |
| Weber, M | 1 |
| Yoon, BW | 1 |
| Tay, KH | 1 |
| Lane, DA | 1 |
| Lip, GY | 1 |
| Schalekamp, T | 1 |
| Klungel, OH | 1 |
| Souverein, PC | 1 |
| de Boer, A | 1 |
| Furlan, AJ | 1 |
| Usman, MH | 1 |
| Notaro, LA | 1 |
| Nagarakanti, R | 1 |
| Brahin, E | 1 |
| Dessain, S | 1 |
| Gracely, E | 1 |
| Ezekowitz, MD | 1 |
| Biller, J | 1 |
| Spinler, SA | 1 |
| Adams, C | 1 |
| Dhirendra, A | 1 |
| Ames, PR | 1 |
| Guthrie, R | 1 |
| Soliman, MM | 1 |
| Arafah, MM | 1 |
| Ferreira-González, L | 1 |
| Trigás-Ferrín, M | 1 |
| Rubin, EP | 1 |
| Sesma, P | 1 |
| Kopp, CW | 1 |
| Steiner, S | 1 |
| Priglinger, U | 1 |
| Christ, G | 1 |
| Probst, P | 1 |
| Maurer, G | 1 |
| Minar, E | 1 |
| Huber, K | 1 |
| Jones, L | 1 |
| Griffin, S | 1 |
| Palmer, S | 1 |
| Main, C | 1 |
| Orton, V | 1 |
| Sculpher, M | 1 |
| Sudlow, C | 1 |
| Henderson, R | 1 |
| Hawkins, N | 1 |
| Riemsma, R | 1 |
| Einhäupl, K | 1 |
| Liao, JK | 1 |
| de Borst, GJ | 1 |
| Hilgevoord, AA | 1 |
| de Vries, JP | 1 |
| van der Mee, M | 1 |
| Moll, FL | 1 |
| van de Pavoordt, HD | 1 |
| Ackerstaff, RG | 1 |
| Macdonald, S | 1 |
| Johnson, SG | 1 |
| Rogers, K | 1 |
| Delate, T | 1 |
| Witt, DM | 1 |
| Schwartz, NE | 1 |
| Kelton, JG | 1 |
| Hirsh, J | 1 |
| Kakkar, VV | 1 |
| Chesebro, JH | 2 |
| Fuster, V | 2 |
| Elveback, LR | 1 |
| McGoon, DC | 1 |
| Pluth, JR | 2 |
| Puga, FJ | 2 |
| Wallace, RB | 1 |
| Danielson, GK | 2 |
| Orszulak, TA | 2 |
| Piehler, JM | 1 |
| Schaff, HV | 1 |
| Page, Y | 1 |
| Lehot, JJ | 1 |
| Rousselet, B | 1 |
| Cognet, JB | 1 |
| Buixuan, B | 1 |
| Hoen, JP | 1 |
| Motin, J | 1 |
| Cohen, AM | 1 |
| Creter, D | 1 |
| Levinsky, UH | 1 |
| Klein, B | 1 |
| Djaldetti, M | 1 |
| Moncada, S | 1 |
| Romem, M | 1 |
| Singer, L | 1 |
| Friedman, C | 1 |
| Heras, M | 1 |
| Penny, WJ | 1 |
| Grill, DE | 1 |
| Bailey, KR | 1 |
| LeBlanc, JG | 1 |
| Sett, SS | 1 |
| Vince, DJ | 1 |
| Fernández-Avilés, F | 1 |
| Alonso, JJ | 1 |
| Durán, JM | 1 |
| Gimeno, F | 1 |
| Muñoz, JC | 1 |
| de la Fuente, L | 1 |
| San Román, JA | 1 |
| Altman, R | 1 |
| Rouvier, J | 1 |
| Gurfinkel, E | 1 |
| Glauber, M | 1 |
| Szefner, J | 1 |
| Senni, M | 1 |
| Gamba, A | 1 |
| Mamprin, F | 1 |
| Fiocchi, R | 1 |
| Somaschini, M | 1 |
| Ferrazzi, P | 1 |
| Griesshammer, M | 1 |
| Heimpel, H | 1 |
| Pearson, TC | 1 |
| Gleiter, CH | 1 |
| Freudenthaler, S | 1 |
| Delabar, U | 1 |
| Eckardt, KU | 1 |
| Mühlbauer, B | 1 |
| Gundert-Remy, U | 1 |
| Osswald, H | 1 |
| Forbes, C | 1 |
| Sivenius, J | 1 |
| Smets, P | 1 |
| Lowenthal, A | 1 |
| Schafer, AI | 1 |
| Iturbe, T | 1 |
| Sánchez, C | 1 |
| Moreno, JA | 1 |
| Olave, T | 1 |
| Azaceta, G | 1 |
| Varo, MJ | 1 |
| Civeira, E | 1 |
| Peleato, J | 1 |
| Cornudella, R | 1 |
| Forbes, CD | 2 |
| Cunningham, RJ | 1 |
| Brouhard, BH | 1 |
| Travis, LB | 1 |
| Berger, M | 1 |
| Petrusick, T | 1 |
| Jobin, F | 1 |
| Conti, A | 1 |
| Nuutinen, LS | 1 |
| Mononen, P | 1 |
| Biale, Y | 1 |
| Lewenthal, H | 1 |
| Gueron, M | 1 |
| Ben-Adereth, N | 1 |
| Kutner, M | 1 |
| Nixon, G | 1 |
| Silverstone, F | 1 |
| Teoh, KH | 3 |
| Weisel, RD | 3 |
| Ivanov, J | 3 |
| Teasdale, SJ | 1 |
| Glynn, MF | 2 |
| Sethi, GK | 1 |
| Copeland, JG | 1 |
| Goldman, S | 1 |
| Moritz, T | 1 |
| Zadina, K | 1 |
| Henderson, WG | 1 |
| DeCampli, WM | 1 |
| Kosek, JC | 1 |
| Mitchell, RS | 1 |
| Handen, CE | 1 |
| Miller, DC | 1 |
| Christakis, GT | 2 |
| Madonik, MM | 2 |
| Wong, PY | 2 |
| Mee, AV | 2 |
| Levitt, D | 1 |
| Benak, A | 1 |
| Reilly, P | 1 |
| Hays, LJ | 1 |
| Beller, GA | 1 |
| Moore, CA | 1 |
| Burwell, LR | 1 |
| Craddock, GB | 1 |
| Gascho, JA | 1 |
| Smucker, ML | 1 |
| Tedesco, C | 1 |
| Nygaard, TW | 1 |
| Levitt, DS | 1 |
| Reilly, PA | 2 |
| Rosenfeld, JM | 1 |
| Pinna, AD | 1 |
| Argiolu, F | 1 |
| Marongiu, L | 1 |
| Pinna, DC | 1 |
| Thompson, M | 1 |
| Bayer, A | 1 |
| Kazim, F | 1 |
| Rosenfeld, J | 1 |
| Lecompte, T | 1 |
| Samama, M | 1 |
| Nuñez, L | 1 |
| Pinto, AG | 1 |
| Larrea, JL | 1 |
| Gil Aguado, M | 1 |
| Connor, FO | 1 |
| Tartaglia, AP | 1 |
| Goldberg, JD | 1 |
| Berk, PD | 1 |
| Wasserman, LR | 1 |
| Verrier, ED | 1 |
| Tranbaugh, RF | 1 |
| Soifer, SJ | 1 |
| Yee, ES | 1 |
| Turley, K | 1 |
| Ebert, PA | 1 |
| Breyer, RH | 1 |
| Rousou, JA | 1 |
| Engelman, RM | 1 |
| Lemeshow, S | 1 |
| Delahaye, JP | 1 |
| Milon, H | 1 |
| Ffrench, P | 1 |
| Philippe-Bert, J | 1 |
| Malquarti, V | 1 |
| Saradarian, W | 1 |
| Bradley, LM | 1 |
| Midgley, FM | 1 |
| Watson, DC | 1 |
| Getson, PR | 1 |
| Scott, LP | 1 |
| Abiko, Y | 1 |
| Minamidate, A | 1 |
| Hashikawa, T | 1 |
| Douglas, AS | 2 |
| Doĭchinov, A | 1 |
| Buchvarova, B | 1 |
| Arieff, AI | 1 |
| Pinggera, WF | 1 |
| Prentice, CR | 1 |
| Becker, RM | 1 |
| Shizgal, HM | 1 |
| Dobell, AR | 1 |
| Powell, HR | 1 |
| Ekert, H | 1 |
| Howenstine, JA | 1 |
| Slaton, P | 1 |
| Spitalny, A | 1 |
| Lee, J | 1 |
| Ogston, D | 1 |
| Byrne, JJ | 1 |
| Migliore, JJ | 1 |
| Beekley, W | 1 |
| Guardione, VA | 1 |
| Williams, LF | 1 |
| Salzman, EW | 1 |
| Harris, WH | 1 |
| DeSanctis, RW | 1 |
| Sherry, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062] | Phase 4 | 20,332 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| "Transcranial Doppler Assessment of Cerebral Embolization During Early Anti-thrombotic Therapy After Bioprosthetic Aortic Valve Replacement: Comparison of High-dose Aspirin Versus Warfarin Plus Low-dose Aspirin"[NCT00465218] | 56 participants (Actual) | Observational | 2007-03-31 | Completed | |||
| In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer[NCT03943966] | 73 participants (Actual) | Interventional | 2019-11-11 | Completed | |||
| Observatory of Anticoagulation After Bioprosthetic Aortic Valve Replacement[NCT01293188] | 434 participants (Actual) | Observational | 2011-01-31 | Completed | |||
| Dabigatran Versus Warfarin After Mitral and Aortic Bioprosthesis Replacement for the Management of Atrial Fibrillation Postoperatively: Pilot Study[NCT01868243] | Phase 2/Phase 3 | 27 participants (Actual) | Interventional | 2013-08-31 | Terminated (stopped due to because a significant decrease of viable candidates for the study.) | ||
| Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery[NCT00420667] | 43 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 1333 |
| Clopidogrel | 1333 |
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 1367 |
| Placebo | 1463 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 916 |
| Clopidogrel | 898 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 880 |
| Placebo | 934 |
(NCT00153062)
Timeframe: Randomization to final patient contact
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 125 |
| Placebo | 151 |
The primary endpoint was the detection of intracardiac thrombus in TEE at the end of follow-up (90 days). (NCT01868243)
Timeframe: 90 days
| Intervention | participants (Number) |
|---|---|
| Dabigatran | 0 |
| Warfarin | 1 |
Spontaneous Echo Contrast showed in Transesophageal echocardiography (NCT01868243)
Timeframe: 90 days
| Intervention | participants (Number) |
|---|---|
| Dabigatran | 2 |
| Warfarin | 1 |
26 reviews available for dipyridamole and Bleeding
| Article | Year |
|---|---|
Antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Factor XI; Fibrinolyt | 2022 |
Interventions for preventing thrombosis in solid organ transplant recipients.
Topics: Anticoagulants; Aspirin; Bias; Dipyridamole; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hum | 2021 |
The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
Topics: Anticoagulants; Aspirin; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Dabigatran; Dipyridamo | 2017 |
Antiplatelet and anticoagulation for patients with prosthetic heart valves.
Topics: Administration, Oral; Anticoagulants; Aspirin; Dipyridamole; Drug Therapy, Combination; Heart Valve | 2013 |
Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Hemorrhage; Humans; Mal | 2013 |
Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study.
Topics: Algorithms; Anticoagulants; Aspirin; Brain Ischemia; Calibration; Cerebral Hemorrhage; Dipyridamole; | 2016 |
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2016 |
Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?
Topics: Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Com | 2009 |
Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clinical Trials as Topic; | 2009 |
Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Hemorrhage; H | 2009 |
Ischemic stroke followed by acute thrombocytopenia: a double iatrogenic whammy.
Topics: Acute Disease; Adult; Brain Ischemia; Dipyridamole; Female; Hemorrhage; Humans; Iatrogenic Disease; | 2011 |
Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Headache; Hemorrhage; Humans; Ischemi | 2011 |
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Delayed-Action Preparations; Diarrhea; Dipyridamole; Dr | 2004 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Use of antiplatelet agents to prevent stroke: what is the role for combinations of medications?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combi | 2008 |
Bleeding associated with antithrombotic therapy.
Topics: 4-Hydroxycoumarins; Aspirin; Dextrans; Dipyridamole; Dose-Response Relationship, Drug; Fibrinolytic | 1980 |
Prevention of venous thromboembolism.
Topics: Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Dextrans; Dihydroergotamine; Dipyridamo | 1981 |
The role of prostacyclin and thromboxane A2 in the regulation of platelet behaviour.
Topics: Aspirin; Dipyridamole; Epoprostenol; Hemorrhage; Humans; Platelet Aggregation; Prostaglandins; Throm | 1980 |
Oral anticoagulant treatment with and without aspirin.
Topics: Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridam | 1995 |
Essential thrombocythemia and pregnancy.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Aspirin; Busulfan; Combined Modality Therapy; Di | 1996 |
Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents.
Topics: Aspirin; Dipyridamole; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Pla | 1997 |
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog | 2000 |
[Long-term antithrombotic treatment in patients with valve prostheses. Practical management and complications].
Topics: Anticoagulants; Aspirin; Bioprosthesis; Dipyridamole; Heart Valve Prosthesis; Hemorrhage; Humans; Th | 1985 |
Management of thrombotic diseases.
Topics: Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Cerebrovascular Disorders; Coronary Dis | 1971 |
Anticoagulants.
Topics: Anticoagulants; Aspirin; Blood Platelet Disorders; Dipyridamole; Enzyme Therapy; Factor IX; Factor V | 1974 |
Anticoagulant and thrombolytic drugs. II. Clinical aspects.
Topics: Administration, Oral; Adult; Anticoagulants; Blood Coagulation Factors; Coronary Disease; Coumarins; | 1971 |
19 trials available for dipyridamole and Bleeding
| Article | Year |
|---|---|
Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia.
Topics: Acute Disease; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female | 2023 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb | 2018 |
Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carotid Artery, Internal, Disse | 2019 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting.
Topics: Adult; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; C | 2003 |
ESPRIT study design and outcomes--a critical appraisal.
Topics: Aspirin; Biomarkers; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; H | 2007 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Heart Valve Prosthesis; | 1983 |
Subacute occlusion, bleeding complications, hospital stay and restenosis after Palmaz-Schatz coronary stenting under a new antithrombotic regimen.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Aspirin; Coronary Angiography; | 1996 |
Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine.
Topics: Adenosine; Adult; Area Under Curve; Cardiovascular Agents; Creatinine; Dipyridamole; Erythropoietin; | 1996 |
European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
Topics: Adult; Aged; Aspirin; Cerebrovascular Disorders; Demography; Dipyridamole; Double-Blind Method; Fema | 1996 |
Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Delayed-Action Preparations; Dipyridamole; Disease-Free Su | 1998 |
Dipyridamole for coronary artery bypass surgery.
Topics: Administration, Oral; Blood Transfusion; Coronary Artery Bypass; Dipyridamole; Erythrocyte Transfusi | 1990 |
Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy.
Topics: Aspirin; Blood Transfusion; Coronary Artery Bypass; Dipyridamole; Double-Blind Method; Graft Occlusi | 1990 |
Blood conservation with membrane oxygenators and dipyridamole.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Blood; Blood Platelets; Clinical Trials as Topic; Contraceptives | 1987 |
Dipyridamole preserved platelets and reduced blood loss after cardiopulmonary bypass.
Topics: Administration, Oral; Aspirin; Blood Platelets; Blood Transfusion; Cardiopulmonary Bypass; Dipyridam | 1988 |
Preservation of platelets and blood products by intravenously administered dipyridamole in patients who undergo coronary artery bypass grafting.
Topics: Aged; Blood Platelets; Blood Transfusion; Coronary Artery Bypass; Dipyridamole; Drug Evaluation; Fem | 1987 |
A critical appraisal of the clinical efficiency of anti-platelet drugs.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1986 |
Reduction in venous thromboembolism by agents affecting platelet function.
Topics: Adult; Aged; Arthroplasty; Aspirin; Blood Platelets; Chromium Alloys; Dextrans; Dipyridamole; Female | 1971 |
39 other studies available for dipyridamole and Bleeding
| Article | Year |
|---|---|
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
Antiplatelet Therapy and Adverse Hematologic Events During Heart Mate II Support.
Topics: Adult; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Dipyridamole; Disease-Free Survival; | 2016 |
Stroke prevention--insights from incoherence.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Dipyridam | 2008 |
Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel any safer than aspirin when combined with warfarin?
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Coumarins; Dipyridamo | 2008 |
Effect of oral antiplatelet agents on major bleeding in users of coumarins.
Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagula | 2008 |
Does the combination of warfarin and aspirin have a place in secondary stroke prevention? Yes.
Topics: Anticoagulants; Aspirin; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combi | 2009 |
Treatment with dipyridamole improves cardiac function and prevent injury in a rat model of hemorrhage.
Topics: Animals; Blood Pressure; Dipyridamole; Disease Models, Animal; Heart; Hemorrhage; Hydrogen-Ion Conce | 2012 |
Pituitary apoplexy after myocardial perfusion scintigraphy.
Topics: Adenoma; Aged; Angina, Unstable; Anticoagulants; Cardiac Pacing, Artificial; Dipyridamole; Female; H | 2012 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Outcomes associated with combined antiplatelet and anticoagulant therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disea | 2008 |
[Use of intravenous dipyridamole as the only antithrombotic agent in the hemodialysis of acute renal failure with a high risk of hemorrhage].
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Dipyridamole; Female; Hemorrhage; Humans; Infusion | 1983 |
Extensive pharyngeal hemorrhage induced by dipyridamole.
Topics: Chlorpropamide; Coronary Disease; Diabetes Mellitus; Dipyridamole; Female; Hemorrhage; Humans; Isoso | 1981 |
[Intraocular hemorrhage due to systemic drugs].
Topics: Adult; Aged; Aspirin; Dipyridamole; Eye Diseases; Female; Hemorrhage; Humans; Male; Middle Aged; Qui | 1982 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
Antiplatelet therapy in children with left-sided mechanical prostheses.
Topics: Adolescent; Aortic Valve; Aspirin; Child; Child, Preschool; Dipyridamole; Female; Follow-Up Studies; | 1993 |
Reduction of haemorrhagic complications during mechanically assisted circulation with the use of a multi-system anticoagulation protocol.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Antithrombin III; Aprotinin; Aspirin; Assisted Circulati | 1995 |
[Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses].
Topics: Acenocoumarol; Adult; Aged; Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Drug Evaluation | 1997 |
Hemorrhage as a complication of dipyridamole therapy.
Topics: Blood Coagulation Tests; Child; Dipyridamole; Female; Hemorrhage; Humans | 1979 |
[Platelet-inhibiting drugs].
Topics: Anti-Bacterial Agents; Aspirin; Dextrans; Dipyridamole; Hemorrhage; Humans; Indomethacin; Platelet A | 1978 |
[Surgical treatment and prevention of acute deep venous thrombosis].
Topics: Aged; Dextrans; Dipyridamole; Hemorrhage; Heparin; Humans; Middle Aged; Pulmonary Embolism; Thrombop | 1976 |
Dipyridamole and thrombocyte count in open-heart surgery.
Topics: Adult; Blood Cell Count; Blood Platelets; Cardiopulmonary Bypass; Dipyridamole; Extracorporeal Circu | 1975 |
Cesarean section in a patient with a mitral valve prosthesis.
Topics: Adult; Cesarean Section; Dipyridamole; Female; Fetal Death; Heart Valve Prosthesis; Hemorrhage; Huma | 1975 |
Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aspirin; Atrial Fibrillation; Attitude of Health Personnel; Cerebrovascu | 1991 |
Effects of aspirin, dipyridamole, and cod liver oil on accelerated myointimal proliferation in canine veno-arterial allografts.
Topics: Animals; Aspirin; Cholesterol, Dietary; Cod Liver Oil; Dipyridamole; Dogs; Elastic Tissue; Endotheli | 1988 |
Short-term infarct vessel patency with aspirin and dipyridamole started 24 to 36 hours after intravenous streptokinase.
Topics: Angiography; Aspirin; Dipyridamole; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardi | 1988 |
Indications and results for splenectomy for beta thalassemia in two hundred and twenty-one pediatric patients.
Topics: Aspirin; Blood Transfusion; Cerebrovascular Disorders; Child; Dipyridamole; Female; Follow-Up Studie | 1988 |
Oral anticoagulation is not necessary for patients with bioprosthetic mitral valve replacement in atrial fibrillation.
Topics: Anticoagulants; Aortic Valve; Aspirin; Atrial Fibrillation; Bioprosthesis; Dipyridamole; Drug Therap | 1986 |
Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera.
Topics: Aspirin; Dipyridamole; Female; Hemorrhage; Humans; Male; Phosphorus Radioisotopes; Platelet Aggregat | 1986 |
Aspirin anticoagulation in children with mechanical aortic valves.
Topics: Adolescent; Adult; Anticoagulants; Aortic Valve; Aspirin; Child; Child, Preschool; Dipyridamole; Fem | 1986 |
Late postoperative tamponade following coronary artery bypass grafting in patients on antiplatelet therapy.
Topics: Adult; Aspirin; Cardiac Tamponade; Coronary Artery Bypass; Dipyridamole; Female; Hemorrhage; Humans; | 1985 |
Anticoagulation therapy in children with mechanical prosthetic cardiac valves.
Topics: Aspirin; Child; Child, Preschool; Dipyridamole; Heart Valve Prosthesis; Hemorrhage; Humans; Thromboe | 1985 |
Discordant response to nitroglycerin of strain gauge arch and maximum rate of rise of left ventricular pressure in dogs.
Topics: Animals; Blood Transfusion; Dipyridamole; Dogs; Female; Heart; Heart Ventricles; Hemorrhage; Male; N | 1972 |
[Long-term medicinal prevention in patients who have suffered myocardial infarction].
Topics: Anti-Arrhythmia Agents; Anticoagulants; Antihypertensive Agents; Clofibrate; Dipyridamole; Drug Ther | 1974 |
Rapidly progressive glomerulonephritis treated with anticoagulants.
Topics: Adult; Aged; Anticoagulants; Azathioprine; Blood Urea Nitrogen; Creatinine; Dipyridamole; Diuresis; | 1972 |
Distribution of coronary blood flow during cardiopulmonary bypass in pigs.
Topics: Animals; Chromium Isotopes; Coronary Circulation; Dipyridamole; Extracorporeal Circulation; Heart Ve | 1973 |
Streptokinase and anti-thrombotic therapy in the hemolytic-uremic syndrome.
Topics: Aspirin; Biopsy; Child; Child, Preschool; Dipyridamole; Hemolytic-Uremic Syndrome; Hemorrhage; Hepar | 1974 |
Flank pain and hematuria in a young man with renal artery arteriosclerosis: remission of symptoms during administration of dipyridamole.
Topics: Adult; Angiography; Arteriosclerosis; Dipyridamole; Hematuria; Hemorrhage; Humans; Ischemia; Kidney; | 1974 |
Platelet response to induction of hemorrhagic pancreatitis.
Topics: Animals; Anti-Bacterial Agents; Aspirin; Blood Cell Count; Dipyridamole; Disease Models, Animal; Dog | 1971 |
Thrombosis prevention.
Topics: Animals; Arteries; Arthroplasty; Aspirin; Blood Platelets; Dextrans; Dipyridamole; Hemorrhage; Hip; | 1971 |